This study will see if interferon-alpha given early in the disease can stop or slow the
immune attack on insulin-producing cells. In addition, the study will examine the safety and
efficacy of interferon-alpha (given by mouth) to protect beta cell function. Patients between
3 and 25 years of age with Type 1 Diabetes Mellitus less then six weeks may be eligible for
this study. All study-related tests and medications at the NIH Clinical Center are provided
at no cost.
Phase:
Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center, Houston
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)